Business Wire

Janssen’s STELARA® (ustekinumab) Demonstrates Sustained Efficacy in Improving Clinical Remission Rates in Patients with Moderate to Severe Crohn’s Disease Throughout Three Years

Del

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the IM-UNITI study, which demonstrates the continued efficacy of ustekinumab in improving clinical remission rates and shows ustekinumab to be generally well-tolerated in patients with Crohn’s disease.1 The data from the IM-UNITI trial, which will continue for a further two years, are being presented today at the 26th United European Gastroenterology Week (UEGW) congress in Vienna, Austria.

These new three-year results from IM-UNITI are encouraging because they show the important role that treatment with ustekinumab can have in helping Crohn’s disease patients to achieve long-term clinical remission,” said Professor William Sandborn, Director, Inflammatory Bowel Disease Center, University of California, San Diego, USA.* “Clinical remission is an important goal during treatment as patients have an improved quality of life and wellbeing when they do not need to worry about a flare up.”

These data are the first to be presented from the three-year assessment of subcutaneously (SC) administered 90 mg ustekinumab in Crohn’s disease. Overall efficacy assessments at week 152 demonstrated that 60.3% of all randomised ustekinumab-treated patients who entered the long-term extension study were in clinical remission. Furthermore, 68.8% of these randomised ustekinumab treated patients had demonstrated a clinical response.1

The key study findings for different dosing regimens found that 61.9% of patients who were randomised to receive 90 mg ustekinumab SC every 12 weeks (q12w) and continued to receive this dose in the study extension were in clinical remission. For those patients who were randomised to receive 90 mg ustekinumab SC in the every eight week dosing regimen group (q8w) and continued to receive this dose, 69.5% of patients were in clinical remission.1

The study also found that, of those patients who were naïve to TNF antagonist therapy and treated with ustekinumab, 67.6% were in clinical remission at week 156.1 This demonstrates that patients who have not yet received TNF antagonist therapy (the most commonly prescribed class of biologic treatments)2 could benefit from ustekinumab treatment. Further to this, of those ustekinumab treated patients who had previously failed (i.e. who were refractory to) or who were intolerant to TNF antagonist therapy, 48.4% were in clinical remission.1

Dr Jaime Oliver, MD, Janssen Therapeutic Area Lead, Immunology, Europe, Middle East & Africa, Cilag GmbH International said, “Janssen is dedicated to helping improve the lives of people living with Crohn’s disease. With that mission in mind, we are pleased that these study findings indicate that ustekinumab can help a substantial proportion of people with moderate to severe Crohn’s disease achieve clinical remission. The IM-UNITI study will continue to explore ustekinumab for a further two years, as part of our ongoing commitment to our patients, innovation and scientific leadership.”

Safety events (per hundred patient years) were not higher amongst all ustekinumab treated patients entering the long-term extension study compared to placebo from week 44 through to week 156. No new safety signals were observed.1

Between weeks 96 and 156, three deaths were reported (one each of acute myocardial infarction, kidney failure and sepsis).1 Additionally, two cases of non-melanoma skin cancers (adenocarcinoma of the small intestine and chronic myeloid leukaemia [CML]) were seen in these ustekinumab treated groups.1

The common (≥1/100) adverse reactions reported in controlled periods of the adult psoriasis, psoriatic arthritis and Crohn's disease clinical studies with ustekinumab as well as post-marketing experience are: arthralgia (joint pain), back pain, diarrhoea, dizziness, fatigue, headache, infection site pain, injection site erythema, myalgia (muscle pain), nasopharyngitis, nausea, oropharyngeal pain, pruritus (itching of the skin), upper respiratory tract infection and vomiting.3

Janssen is presenting a total of four abstracts at this year’s UEGW congress, including further data from the UNITI clinical trial programme, as well as a late breaking abstract presenting data from the UNIFI clinical trial programme assessing ustekinumab’s efficacy in moderate to severe ulcerative colitis patients.4

#ENDS#

*Professor William Sandborn is a paid consultant for Janssen. He was not compensated for any media work.

About UEGW

The United European Gastroenterology Week (UEGW) congress is taking place in Vienna, Austria from Saturday 20th to Wednesday 24th October 2018. For more information, visit: https://www.ueg.eu/week/.

About Crohn’s disease

Up to one million people across Europe are living with Crohn’s disease, and nearly 33,000 new cases are diagnosed each year.5 Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract with no known cause, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition, diet or other environmental factors. Symptoms of Crohn’s disease can vary but often include abdominal pain and tenderness, frequent diarrhoea, rectal bleeding, weight loss and fever. There is currently no cure for Crohn’s disease.6

About the IM-UNITI trial

IM-UNITI, a Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel group study, evaluated the efficacy and safety of ustekinumab maintenance therapy in adult patients with moderate-to-severe Crohn’s disease. Patients who had responded to a single intravenous dose of ustekinumab in the UNITI-1 or UNITI-2 induction studies were randomised equally to receive maintenance subcutaneous (SC) ustekinumab 90mg q8w or q12w, or placebo. In patients who met loss of response criteria between weeks 8–32, a one-time dose adjustment to 90mg q8w occurred. All patients completing week 44 were eligible to enter the long-term extension programme, continuing their current regimen up to week 152. Patients will continue in the IM-UNITI trial up to week 252.

About STELARA ® (ustekinumab) 3

In the European Union, ustekinumab is approved for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or psoralen plus ultraviolet A (PUVA), and is also indicated for the treatment of moderate-to-severe plaque psoriasis in adolescent patients from the age of 12 years and older who are inadequately controlled by or are intolerant to other systemic therapies or phototherapies. In addition, ustekinumab is approved alone or in combination with MTX for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying antirheumatic drug (DMARD) therapy has been inadequate. In November 2016, the European Commission approved ustekinumab for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-alpha antagonist or have medical contraindications to such therapies.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science.

We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/EMEA. Follow us on Twitter: @JanssenEMEA.

Janssen-Cilag International NV and Cilag GmbH International are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

###

References

1. Sandborn W, Rutgeerts P, et al. Efficacy and safety of ustekinumab for Crohn’s disease: Results from IM-UNITI long-term extension through 3 years. United European Gastroenterology Week (UEGW 2018) 20–24 October, 2018;Vienna, Austria.

2. Crohn’s & Colitis UK. Biological drugs: Information sheet. Available at: http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/Biologic-drugs-in-ibd. Last accessed October 2018.

3. European Medicines Agency. (2018) Ustekinumab Summary of Product Characteristics. Available at: https://www.ema.europa.eu/documents/product-information/stelara-epar-product-information_en.pdf. Accessed October 2018.

4. Sands B, Sandborn W, et al. Safety and efficacy of ustekinumab induction therapy in patients with moderate to severe ulcerative colitis: results from the Phase 3 UNIFI study. United Europe Gastroenterology Week (UEGW) 2018 20–24 Oct 2018;Vienna, Austria:LB01.

5. Janssen Disease Lens. Ulcerative colitis. Available at: https://www.crohnsandcolitis.org.uk/about-inflammatory-bowel-disease/ulcerative-colitis. Accessed October 2018.

6. Crohn’s and Colitis UK. Crohn’s disease. Available at: http://www.crohnsandcolitis.org.uk/about-inflammatory-bowel-disease/crohns-disease. Accessed October 2018.

Contact information

Media Enquiries:
Emily Bone
Mobile: +44 7876 394 360
Email: ebone1@ITS.JNJ.com
or
Investor Relations:
Christopher DelOrefice
Phone: +1 732-524-2955
or
Lesley Fishman
Phone: +1 732-524-3922

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AGCO Focuses on Animal Welfare17.1.2019 10:00Pressemelding

AGCO (NYSE: AGCO), a global leader in manufacturing and the distribution of agricultural equipment and solutions, today hosted its annual AGCO Berlin Summit. The international industry event aims to bring together decision-makers in politics, economy and society to share their experiences and discuss the future of the agricultural industry. Today’s ‘Feeding the World - The Future for Protein’ summit was focused on aspects of animal welfare in the context of modern agriculture, including the need for sustainable protein production to meet an increasing demand for protein-rich foods. The AGCO Berlin Summit is a joint initiative of AGCO and the new AGCO Agriculture Foundation. The AGCO Agriculture Foundation develops charitable initiatives to enhance global food security, sustainable agricultural development and positive economic impacts, particularly in developing countries. As in previous years, AGCO Finance and AGCO Fuse Technologies are sponsors of the 2019 AGCO Berlin Summit. "Whilst

Mr. Paul Bridwell Joins OpenGate Capital in Senior Operations Role for North America17.1.2019 08:00Pressemelding

OpenGate Capital, a global private equity firm, announced that Mr. Paul Bridwell joined the firm on November 5th, 2018, as Managing Director to lead operations and portfolio management for the firm’s North American-based investments. Based in Los Angeles, Bridwell joins the OpenGate senior leadership team as a member of the firm’s Investment and Portfolio Committees. Bridwell is a tenured professional with 15 years of private equity experience and has a proven track record of delivering operating results leading to superior investor returns. He possesses solid leadership and organizational skills both as portfolio company CEO and as an operations leader developed through his tenure at two global, private equity firms. Prior to joining OpenGate, Bridwell was Partner and Managing Director – Head of Operations at a major private equity investment firm in New York City, where he established the firm’s first operations-focused group and developed a comprehensive operations approach compatib

Anywhere365 Introduces Web Agent for Microsoft Dynamics 36517.1.2019 07:00Pressemelding

Workstreampeople, a global leader in contact center solutions for Skype for Business and Microsoft Teams, today announced the introduction of the Anywhere365 Web Agent for Microsoft Dynamics 365. Based on the Dynamics 365 Channel Integration Framework (CIF) the Web Agent is nested in the Dynamics 365 interface and provides users with Anywhere365’s omni-channel contact center functionality without having to move between applications. The Dynamics 365 client is automatically resized to accommodate the Web Agent ensuring none of the user interface is masked. Agents can receive, send, and automatically log calls, chats, emails and video all from within Dynamics 365, improving the efficiency and accuracy of customer interactions. From the Anywhere365 Web Agent, Dynamics 365 users can control media interactions and monitor real-time queue information. Integration with Microsoft Azure services provides automatic language detection and real-time translation of chat and voice interactions betwe

Ipsen Presents the Results of the First in-Human Study of a Recombinant Fast-Acting Neurotoxin (rBoNT-E) at TOXINS 201917.1.2019 06:30Pressemelding

Regulatory News: Results of the first in-human study of a recombinant neurotoxin are being presented at the TOXINS International Conference in Copenhagen. Ipsen’s recombinant BoNT serotype E (rBoNT-E) was investigated in a phase I study that demonstrated its safety and tolerability profile in healthy volunteers1. The study also reported that it has a faster onset of action and a shorter duration of effect, as well as a quick time to peak activity, in comparison with established BoNT-A products. Further studies will be initiated to establish potential aesthetic and therapeutic uses of this investigational therapy. “The application of recombinant techniques to create novel botulinum toxin-based medicines with different onsets and durations of action, will potentially offer clinicians the flexibility to choose the most appropriate neurotoxin for each patient, which is not an option today,” said Philippe Picaut, Pharm. D., PhD, Senior Vice President Research & Development for the Neuroscie

NTT Communications to Expand Ecosystem for Interconnection of Major Data Centers in Japan17.1.2019 03:04Pressemelding

NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO:9432), announced today that it will expand the interconnection of its Nexcenter™ data centers in Tokyo and Osaka, Japan to enable client companies to connect with cloud and content services more flexibly than ever before. On a sequential basis from this month, NTT Com will begin directly connecting its ecosystem with three major internet exchanges (IXs) in Japan to enable clients to access services offered by these IXs and various NTT Com partner companies. Thereafter, NTT Com will continue to expand this ecosystem centered on NTT Com’s Nexcenter™ data centers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190116005908/en/ Expanding Interconnection (Graphic: Business Wire) As a DX Enabler™, NTT Com uses ICT to achieve digital transformation (DX) "Transform and create business" together with clien

Piraeus Bank Presents the Principles for Responsible Banking with the Governor of the Bank of Greece16.1.2019 18:21Pressemelding

The Principles for Responsible Banking were presented today for the first time in Greece at an event organized by Piraeus Bank with Mr. Yannis Stournaras, the Governor of the Bank of Greece, as the keynote speaker. The event was organised as part of Piraeus Bank’s commitment to the United Nations Environment Programme Finance Initiative (UNEP FI). Piraeus is the only Greek bank to be a member of the global initiative, which includes twenty-eight banks from around the world, representing over USD 17 trillion in combined assets. Mr. Yannis Stournaras, the Governor of Bank of Greece, highlighted in his speech that the Bank of Greece fully supports the Principles for Responsible Banking and urges all of the banks to endorse the Principles and set ambitious targets. The Bank of Greece was one of the first central banks to become involved with the climate change issue, establishing the Climate Change Impacts Study Committee in 2009 and investing in one of the most significant Sustainable Dev